Ambit Biosciences Corp (AMBI) 6.96 $AMBI
Nasdaq stocks posting largest percentage increases
AP - Fri May 09, 12:20PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Ambit Biosciences Announces First Quarter 2014 Operating Results
PR Newswire - Tue May 06, 3:05PM CDT
Ambit Biosciences (NASDAQ: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced operating results for the first quarter 2014. The company will host a conference call today to discuss financial results for the first quarter, and to provide an update on plans and activities for 2014.
Ambit Announces Participation At Deutsche Bank 39th Annual Healthcare Conference
PR Newswire - Thu May 01, 6:30AM CDT
Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Deutsche Bank 39th Annual Healthcare Conference to be held at the InterContinental Hotel in Boston, MA, May 7-8, 2014.
Global Refractory Acute Myeloid Leukemia Clinical Trials Review 2014
M2 - Tue Apr 29, 5:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tpqqxj/refractory_acute) has announced the addition of the "Global Refractory Acute Myeloid Leukemia Clinical Trials Review 2014" report to their offering. Refractory Acute Myeloid Leukemia Global Clinical Trials Review, H1, 2014" provides data on the Refractory Acute Myeloid Leukemia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Refractory Acute Myeloid Leukemia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Refractory Acute Myeloid Leukemia. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies/Institutions - Novartis AG - Pfizer Inc. - Celgene Corporation - Sanofi - C. H. Boehringer Sohn AG & Co. KG - Ambit Biosciences Corporation - F. Hoffmann-La Roche Ltd. - AROG Pharmaceuticals LLC - Amgen Inc. - AbbVie Inc. - National Cancer Institute - Fred Hutchinson Cancer Research Center - Children's Oncology Group - The University of Texas M. D. Anderson Cancer Center - Stanford University - Washington University School of Medicine - Roswell Park Cancer Institute - Sidney Kimmel Comprehensive Cancer Center - Case Comprehensive Cancer Center For more information visit http://www.researchandmarkets.com/research/tp...tory_acute
Global Gastrointestinal Stromal Tumor (GIST) Therapeutics Pipeline Review 2014 - Analysis of 16 Companies & 23 Drug Profiles
M2 - Mon Apr 28, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8rx8bp/gastrointestinal) has announced the addition of the "Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Gastrointestinal Stromal Tumor (GIST), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastrointestinal Stromal Tumor (GIST) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (GIST) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Gastrointestinal Stromal Tumor (GIST) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Gastrointestinal Stromal Tumor (GIST) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Eli Lilly and Company - Novartis AG - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - Bayer AG - Ariad Pharmaceuticals, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chipscreen Biosciences Ltd - Ambit Biosciences Corporation - Deciphera Pharmaceuticals, LLC - Xcovery, Inc. - AB Science - Clovis Oncology, Inc. - EirGen Pharma Ltd. - AROG Pharmaceuticals LLC Drug Profiles - regorafenib - masitinib - nilotinib - masitinib - olaratumab - linsitinib - ponatinib - AT-13387 - ganetespib - dovitinib lactate - crenolanib - luminespib - MEK-162 - TH-302 - buparlisib hydrochloride - CS-2164 - Mixed Bacterial Vaccine - X-82 - quizartinib - DCC-2618 - Mutant cKIT Inhibitor - Drug Targeting c-Kit - Eir-108 For more information visit http://www.researchandmarkets.com/research/8r...intestinal
Ambit Biosciences Slumps: AMBI Falls 7.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 7:49AM CDT
Ambit Biosciences saw a big move last session, as the company’s shares fell by over 7% on the day
Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology
PR Newswire - Tue Apr 22, 3:01PM CDT
Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced two abstracts to be presented at the Annual Meeting of the American Society of Clinical Oncology, held May 30 through June 3, 2014, at McCormick Place in Chicago.
Ambit Biosciences to Announce First Quarter 2014 Financial Results
PR Newswire - Tue Apr 22, 6:30AM CDT
Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced it will report first quarter operational results after closing of the NASDAQ Global Market on Tuesday, May 6, 2014.
Ambit Biosciences Slumps: AMBI Falls 13.0% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 7:40AM CDT
Ambit Biosciences falls 13% last trading session, continuing the downtrend
Ambit's Oncology Drug in Phase III - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 3:55PM CDT
Ambit Biosciences commenced a phase III study (QUANTUM-R) on its lead oncology candidate, quizartinib for acute myeloid leukemia (AML).
Ambit Announces Initiation Of Quizartinib QUANTUM-R Phase 3 Trial
PR Newswire - Tue Apr 08, 6:30AM CDT
Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the QUANTUM-R Phase 3 clinical trial comparing quizartinib as monotherapy to chemotherapy regimens in relapsed/refractory acute myeloid leukemia (AML) patients with the FMS-like tyrosine kinase-3 (FLT3)-ITD mutation.
Ambit Announces Initiation Of Phase 2 Cohort In MD Anderson Sponsored Study Of Quizartinib In AML And High Risk MDS
PR Newswire - Mon Apr 07, 6:30AM CDT
Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the Phase 2 cohort of the MD Anderson Cancer Center-sponsored Phase 1/2 study of quizartinib in combination with either 5-azacitidine or low dose cytarabine for previously untreated FLT3-ITD positive acute myeloid leukemia (AML) patients age 60 or older, or FLT3-ITD positive AML patients 18 years of age or older in first relapse.
Global Pharmaceutical and Biotechnology Outlook 2014: Rising Stars
M2 - Thu Mar 27, 4:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/234sqv/global) has announced the addition of the "Global Pharmaceutical and Biotechnology Outlook 2014: Rising Stars" report to their offering. Innovations have contributed to the availability of a range of new treatments for diseases resulting in improvements in the length and quality of life and reduced disease burden for individuals and society. However, the need for innovative therapies for unmet needs /challenging diseases continues to grow, accelerating the pace of drug development directly or through partnership/ in-licensing. The authors expect innovation and improved drugs therapies through novel target discovery and technology platforms to continue to flow from the backyards of small research focused companies (Rising Stars, RS - non-profitable biotech companies) in coming years. Approval of new drugs, successful launches, maturing pipeline sustained the growth trajectory of biotech companies resulting in successful IPOs. The authors expect the optimism to percolate further into companies with novel technology platforms and targets. For more details on the trend in drug approvals, upcoming milestones and M&A in coming years please see Global Pharmaceutical and Biotechnology Outlook 2014: Rising Stars Key Topics Covered: Macro Analysis PI3K, Jak and BTK inhibitors in clinical development In-depth Company Analysis 1. Ablynx- Nanobodies - Turnarond on the Horizon 2. Ambit Biosciences- Quizartinib in RR-AML = Delayed but not Dead 3. Basilea- Drugs for Bad Bugs Isavuconazole- Watch out for ACTIVE and VITAL 4.Cempra (CEMP) 5. Endocyte 6. Enanata- The Party to Continue in 2014 - 2nd in the Oral IFN-free HCV Drug Race 7. Galapagos- Drug Discovery platform driving robust Partnership -AbbVie, GSK, Janssen,Servier. 8. Incyte - INCB39110 - Another JAK-Fruit in INCY's Bucket Leader in the Jak- 2 Inhibitor Space 9. ISIS - Beyond KYNAMRO - Targeting Other Niche Indications 10. Morphosys - MOR103/ MOR202 - Partnering is the Beginning of a New Phase of Growth 11. Onconova- ONTIME - Holds the Key! 12. Pharmacyclics- Ibrutinib Therapy: A Game Changer for Leukemia 13. SymBio (4582 JP) Future Growth-TREAKISYM's Label Expansion and Rigosertib's Success Industry Tables 1. Drug Clinical Milestones 2. Drug Launch Table- 2014 Companies Mentioned: - Ablynx - Ambit Bioscience - Basilea - Cempra - Enanata - Endocyte - Galapagos - Incyte - ISIS Pharma - MorphoSys - Onconova - Pharmacyclics - SymBio For more information visit http://www.researchandmarkets.com/research/234sqv/global
Concise Analysis of New Methods for Treating Refractory Hematological Malignancies - Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
M2 - Wed Mar 26, 4:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6bg256/treating) has announced the addition of the "Concise Analysis of New Methods for Treating Refractory Hematological Malignancies - Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)" report to their offering. Targeting unmet needs in the treatment of cancer through innovative drug development strategies have witnessed favourable outcomes recently. New targets have been validated in this process where kinases lead the way. The success has boosted the innovative biotech sector and is reflected in the performance of the IPOs' since 2010 till date. Positive clinical data/ regulatory approval, lucrative partnership/ acquisition announcement have increased the confidence of investors on innovation and whetted their appetite for risk associated with innovation! Several companies that have recently made their debut in public (NASDAQ) are addressing unmet needs/ niche indications with novel technology platforms/targets. Earlier, the authors had highlighted the investment opportunity and drugs being developed for Relapsed and Refractory Multiple Myeloma (RRMM). Approval of Kyprolis (carfilzomib, Onyx), Pomalyst (pomalidomide, Celgene) for this indication and their successful commercial launch validate the strategy deployed by the companies. They expect a similar scenario to unfold in the treatment of recurrent/ refractory MDS (RR-MDS, High-Risk MDS), and AML (relapsed/ refractory AML, R/R AML) and in this report highlight the new drugs and companies developing these drugs. Key Topics Covered: 1. Executive Summary 2. Investment Drivers of The Select Companies Covered 3. Myelodysplastic syndrome (MDS) 4. Acute Myelogenous Leukemia (AML) 5. Competitive Landscape: RR/ High-Risk MDS and RR AML 6. Competitive Landscape: Untreated/ Newly Diagnosed MDS and AML 7. Key Milestones 8. Launch Timeline and Commercial Opportunity of Late-stage Pipeline (RR MDS and RR AML) 9. Drivers of M&A / Licensing Deals in MDS/ AML 10.1 Ambit Biosciences (AMBI) Products Mentioned: - AC 220 - BI 6727 - C-kit positive - CPX-351 - Celgene - Elderly AML - Estybon - FLT3 mutation - IPSS-R - Quizartinib - R/R AML - Sapacitabine - Sunesis - SymBio - Vidaza - Volasertib - Vosaroxin - azacitidine - decitabine - high risk - higher risk - intermediate-1 - intermediate-2 - kinase - lower risk - lower risk - newly diagnosed - older AML - refractory - relapsed - rigosertib - stem cell transplantation For more information visit http://www.researchandmarkets.com/research/6bg256/treating
Ambit Biosciences posts lower consolidated net loss of USD11.26m in 2013
M2 - Fri Mar 21, 7:16AM CDT
Biopharmaceutical company Ambit Biosciences (NasdaqGM:AMBI) on Thursday reported a consolidated net loss of USD11.26m in 2013.
Ambit Biosciences Announces Fourth Quarter And Full-Year 2013 Operating Results
PR Newswire - Thu Mar 20, 3:10PM CDT
Ambit Biosciences (NASDAQ: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced fourth quarter and full-year operating results for 2013. The company will host a conference call today to discuss financial results for the fourth quarter and full-year 2013, and to provide an outlook on plans for 2014.
Ambit Biosciences to Announce Fourth Quarter and full-year 2013 Financial Results
PR Newswire - Thu Mar 06, 6:00AM CST
Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced it will report fourth quarter and full-year 2013 operational results after closing of the NASDAQ Global Market on Thursday, March 20, 2014.
Ambit Announces Participation At Barclays Global Healthcare Conference
PR Newswire - Tue Mar 04, 6:00AM CST
Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Barclays Global Healthcare Conference to be held at the Loews Miami Hotel in Miami Beach, FL, March 10-13, 2014.
Ambit Announces Participation At Leerink Global Healthcare Conference
PR Newswire - Tue Feb 04, 6:00AM CST
Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Leerink Global Healthcare Conference to be held at the Waldorf Astoria in New York City, February 12-13, 2014.
Ambit Biosciences hires Mark Foletta to board
M2 - Tue Jan 28, 5:23AM CST
Biopharmaceutical company Ambit Biosciences (NasdaqGM:AMBI) reported on Monday the election of of Mark G Foletta to its board of directors, as well as chair of its audit committee.
Nasdaq stocks posting largest percentage increases
AP - Fri May 09, 12:20PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Ambit Biosciences Announces First Quarter 2014 Operating Results
PR Newswire - Tue May 06, 3:05PM CDT
Ambit Biosciences (NASDAQ: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced operating results for the first quarter 2014. The company will host a conference call today to discuss financial results for the first quarter, and to provide an update on plans and activities for 2014.
Ambit Announces Participation At Deutsche Bank 39th Annual Healthcare Conference
PR Newswire - Thu May 01, 6:30AM CDT
Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Deutsche Bank 39th Annual Healthcare Conference to be held at the InterContinental Hotel in Boston, MA, May 7-8, 2014.
Global Refractory Acute Myeloid Leukemia Clinical Trials Review 2014
M2 - Tue Apr 29, 5:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tpqqxj/refractory_acute) has announced the addition of the "Global Refractory Acute Myeloid Leukemia Clinical Trials Review 2014" report to their offering. Refractory Acute Myeloid Leukemia Global Clinical Trials Review, H1, 2014" provides data on the Refractory Acute Myeloid Leukemia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Refractory Acute Myeloid Leukemia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Refractory Acute Myeloid Leukemia. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies/Institutions - Novartis AG - Pfizer Inc. - Celgene Corporation - Sanofi - C. H. Boehringer Sohn AG & Co. KG - Ambit Biosciences Corporation - F. Hoffmann-La Roche Ltd. - AROG Pharmaceuticals LLC - Amgen Inc. - AbbVie Inc. - National Cancer Institute - Fred Hutchinson Cancer Research Center - Children's Oncology Group - The University of Texas M. D. Anderson Cancer Center - Stanford University - Washington University School of Medicine - Roswell Park Cancer Institute - Sidney Kimmel Comprehensive Cancer Center - Case Comprehensive Cancer Center For more information visit http://www.researchandmarkets.com/research/tp...tory_acute
Global Gastrointestinal Stromal Tumor (GIST) Therapeutics Pipeline Review 2014 - Analysis of 16 Companies & 23 Drug Profiles
M2 - Mon Apr 28, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8rx8bp/gastrointestinal) has announced the addition of the "Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Gastrointestinal Stromal Tumor (GIST), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastrointestinal Stromal Tumor (GIST) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (GIST) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Gastrointestinal Stromal Tumor (GIST) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Gastrointestinal Stromal Tumor (GIST) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Eli Lilly and Company - Novartis AG - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - Bayer AG - Ariad Pharmaceuticals, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chipscreen Biosciences Ltd - Ambit Biosciences Corporation - Deciphera Pharmaceuticals, LLC - Xcovery, Inc. - AB Science - Clovis Oncology, Inc. - EirGen Pharma Ltd. - AROG Pharmaceuticals LLC Drug Profiles - regorafenib - masitinib - nilotinib - masitinib - olaratumab - linsitinib - ponatinib - AT-13387 - ganetespib - dovitinib lactate - crenolanib - luminespib - MEK-162 - TH-302 - buparlisib hydrochloride - CS-2164 - Mixed Bacterial Vaccine - X-82 - quizartinib - DCC-2618 - Mutant cKIT Inhibitor - Drug Targeting c-Kit - Eir-108 For more information visit http://www.researchandmarkets.com/research/8r...intestinal
Ambit Biosciences Slumps: AMBI Falls 7.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 7:49AM CDT
Ambit Biosciences saw a big move last session, as the company’s shares fell by over 7% on the day
Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology
PR Newswire - Tue Apr 22, 3:01PM CDT
Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced two abstracts to be presented at the Annual Meeting of the American Society of Clinical Oncology, held May 30 through June 3, 2014, at McCormick Place in Chicago.
Ambit Biosciences to Announce First Quarter 2014 Financial Results
PR Newswire - Tue Apr 22, 6:30AM CDT
Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced it will report first quarter operational results after closing of the NASDAQ Global Market on Tuesday, May 6, 2014.
Ambit Biosciences Slumps: AMBI Falls 13.0% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 7:40AM CDT
Ambit Biosciences falls 13% last trading session, continuing the downtrend
Ambit's Oncology Drug in Phase III - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 3:55PM CDT
Ambit Biosciences commenced a phase III study (QUANTUM-R) on its lead oncology candidate, quizartinib for acute myeloid leukemia (AML).
Ambit Announces Initiation Of Quizartinib QUANTUM-R Phase 3 Trial
PR Newswire - Tue Apr 08, 6:30AM CDT
Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the QUANTUM-R Phase 3 clinical trial comparing quizartinib as monotherapy to chemotherapy regimens in relapsed/refractory acute myeloid leukemia (AML) patients with the FMS-like tyrosine kinase-3 (FLT3)-ITD mutation.
Ambit Announces Initiation Of Phase 2 Cohort In MD Anderson Sponsored Study Of Quizartinib In AML And High Risk MDS
PR Newswire - Mon Apr 07, 6:30AM CDT
Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the Phase 2 cohort of the MD Anderson Cancer Center-sponsored Phase 1/2 study of quizartinib in combination with either 5-azacitidine or low dose cytarabine for previously untreated FLT3-ITD positive acute myeloid leukemia (AML) patients age 60 or older, or FLT3-ITD positive AML patients 18 years of age or older in first relapse.
Global Pharmaceutical and Biotechnology Outlook 2014: Rising Stars
M2 - Thu Mar 27, 4:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/234sqv/global) has announced the addition of the "Global Pharmaceutical and Biotechnology Outlook 2014: Rising Stars" report to their offering. Innovations have contributed to the availability of a range of new treatments for diseases resulting in improvements in the length and quality of life and reduced disease burden for individuals and society. However, the need for innovative therapies for unmet needs /challenging diseases continues to grow, accelerating the pace of drug development directly or through partnership/ in-licensing. The authors expect innovation and improved drugs therapies through novel target discovery and technology platforms to continue to flow from the backyards of small research focused companies (Rising Stars, RS - non-profitable biotech companies) in coming years. Approval of new drugs, successful launches, maturing pipeline sustained the growth trajectory of biotech companies resulting in successful IPOs. The authors expect the optimism to percolate further into companies with novel technology platforms and targets. For more details on the trend in drug approvals, upcoming milestones and M&A in coming years please see Global Pharmaceutical and Biotechnology Outlook 2014: Rising Stars Key Topics Covered: Macro Analysis PI3K, Jak and BTK inhibitors in clinical development In-depth Company Analysis 1. Ablynx- Nanobodies - Turnarond on the Horizon 2. Ambit Biosciences- Quizartinib in RR-AML = Delayed but not Dead 3. Basilea- Drugs for Bad Bugs Isavuconazole- Watch out for ACTIVE and VITAL 4.Cempra (CEMP) 5. Endocyte 6. Enanata- The Party to Continue in 2014 - 2nd in the Oral IFN-free HCV Drug Race 7. Galapagos- Drug Discovery platform driving robust Partnership -AbbVie, GSK, Janssen,Servier. 8. Incyte - INCB39110 - Another JAK-Fruit in INCY's Bucket Leader in the Jak- 2 Inhibitor Space 9. ISIS - Beyond KYNAMRO - Targeting Other Niche Indications 10. Morphosys - MOR103/ MOR202 - Partnering is the Beginning of a New Phase of Growth 11. Onconova- ONTIME - Holds the Key! 12. Pharmacyclics- Ibrutinib Therapy: A Game Changer for Leukemia 13. SymBio (4582 JP) Future Growth-TREAKISYM's Label Expansion and Rigosertib's Success Industry Tables 1. Drug Clinical Milestones 2. Drug Launch Table- 2014 Companies Mentioned: - Ablynx - Ambit Bioscience - Basilea - Cempra - Enanata - Endocyte - Galapagos - Incyte - ISIS Pharma - MorphoSys - Onconova - Pharmacyclics - SymBio For more information visit http://www.researchandmarkets.com/research/234sqv/global
Concise Analysis of New Methods for Treating Refractory Hematological Malignancies - Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
M2 - Wed Mar 26, 4:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6bg256/treating) has announced the addition of the "Concise Analysis of New Methods for Treating Refractory Hematological Malignancies - Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)" report to their offering. Targeting unmet needs in the treatment of cancer through innovative drug development strategies have witnessed favourable outcomes recently. New targets have been validated in this process where kinases lead the way. The success has boosted the innovative biotech sector and is reflected in the performance of the IPOs' since 2010 till date. Positive clinical data/ regulatory approval, lucrative partnership/ acquisition announcement have increased the confidence of investors on innovation and whetted their appetite for risk associated with innovation! Several companies that have recently made their debut in public (NASDAQ) are addressing unmet needs/ niche indications with novel technology platforms/targets. Earlier, the authors had highlighted the investment opportunity and drugs being developed for Relapsed and Refractory Multiple Myeloma (RRMM). Approval of Kyprolis (carfilzomib, Onyx), Pomalyst (pomalidomide, Celgene) for this indication and their successful commercial launch validate the strategy deployed by the companies. They expect a similar scenario to unfold in the treatment of recurrent/ refractory MDS (RR-MDS, High-Risk MDS), and AML (relapsed/ refractory AML, R/R AML) and in this report highlight the new drugs and companies developing these drugs. Key Topics Covered: 1. Executive Summary 2. Investment Drivers of The Select Companies Covered 3. Myelodysplastic syndrome (MDS) 4. Acute Myelogenous Leukemia (AML) 5. Competitive Landscape: RR/ High-Risk MDS and RR AML 6. Competitive Landscape: Untreated/ Newly Diagnosed MDS and AML 7. Key Milestones 8. Launch Timeline and Commercial Opportunity of Late-stage Pipeline (RR MDS and RR AML) 9. Drivers of M&A / Licensing Deals in MDS/ AML 10.1 Ambit Biosciences (AMBI) Products Mentioned: - AC 220 - BI 6727 - C-kit positive - CPX-351 - Celgene - Elderly AML - Estybon - FLT3 mutation - IPSS-R - Quizartinib - R/R AML - Sapacitabine - Sunesis - SymBio - Vidaza - Volasertib - Vosaroxin - azacitidine - decitabine - high risk - higher risk - intermediate-1 - intermediate-2 - kinase - lower risk - lower risk - newly diagnosed - older AML - refractory - relapsed - rigosertib - stem cell transplantation For more information visit http://www.researchandmarkets.com/research/6bg256/treating
Ambit Biosciences posts lower consolidated net loss of USD11.26m in 2013
M2 - Fri Mar 21, 7:16AM CDT
Biopharmaceutical company Ambit Biosciences (NasdaqGM:AMBI) on Thursday reported a consolidated net loss of USD11.26m in 2013.
Ambit Biosciences Announces Fourth Quarter And Full-Year 2013 Operating Results
PR Newswire - Thu Mar 20, 3:10PM CDT
Ambit Biosciences (NASDAQ: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced fourth quarter and full-year operating results for 2013. The company will host a conference call today to discuss financial results for the fourth quarter and full-year 2013, and to provide an outlook on plans for 2014.
Ambit Biosciences to Announce Fourth Quarter and full-year 2013 Financial Results
PR Newswire - Thu Mar 06, 6:00AM CST
Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced it will report fourth quarter and full-year 2013 operational results after closing of the NASDAQ Global Market on Thursday, March 20, 2014.
Ambit Announces Participation At Barclays Global Healthcare Conference
PR Newswire - Tue Mar 04, 6:00AM CST
Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Barclays Global Healthcare Conference to be held at the Loews Miami Hotel in Miami Beach, FL, March 10-13, 2014.
Ambit Announces Participation At Leerink Global Healthcare Conference
PR Newswire - Tue Feb 04, 6:00AM CST
Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Leerink Global Healthcare Conference to be held at the Waldorf Astoria in New York City, February 12-13, 2014.
Ambit Biosciences hires Mark Foletta to board
M2 - Tue Jan 28, 5:23AM CST
Biopharmaceutical company Ambit Biosciences (NasdaqGM:AMBI) reported on Monday the election of of Mark G Foletta to its board of directors, as well as chair of its audit committee.
